Related by context. Frequent words. (Click for all words.) 88 Initiates Phase II 86 Receives Orphan Drug Designation 85 Completes Enrollment 85 Presents Positive 84 Meets Primary Endpoint 82 Enrolls First 81 Announces FDA Clearance 81 Commences Phase 79 Initiates Phase 79 Pivotal Phase III 79 Patient Enrollment 79 Initiate Phase 78 Inc Therapeutic Competitors 78 FDA Accepts 78 Announces Initiation 78 Clinical Trial Results 78 FDA Clears 78 Drug Candidate 78 Receives FDA Clearance 77 Phase III Clinical Trial 77 Develop Novel 76 Preclinical Data 76 Files Shelf Registration Statement 76 Phase III Trial 76 Pivotal Study 76 Improves Survival 75 Single Dose 75 Generic Version 75 Significantly Improves 75 Drug Shows Promise 75 Pivotal Trial 75 Therapeutic Competitors 75 Jumps Higher 75 Kuvan R 75 Pivotal Phase 75 gets USFDA nod 75 Announces Presentation 74 Sapacitabine 74 Study Demonstrates 74 Q2 Loss Narrows 73 Arthritis Drug 73 Inc. NASDAQ QLTI 73 Q1 Loss Narrows 73 Inc. Nasdaq IMGN 73 Receives Patent 73 Signs License Agreement 73 R sorafenib tablets 73 Welcomes Analyst Initiation 73 CHEAP ONLINE PHARMACY LOW 73 Announces Successful Completion 73 refractory chronic lymphocytic 73 Achieves Milestone 73 Q3 Loss Widens 72 Significantly Reduces 72 Recombinant Human 72 Q3 Loss Narrows 72 Signs Licensing Agreement 72 Announces Publication 72 Takeda Kyowa Hakko Kirin 72 Q2 Loss Widens 72 Q4 Loss Narrows 72 Receives CE 72 Panzem R 72 Report companiesandmarkets.com adds 72 Pulmonary Arterial Hypertension 72 Small Molecule 72 Transcept Pharmaceuticals 72 Provides Shareholder 72 Q4 Loss Widens 72 Osteoporosis Drug 72 Application MAA 72 Announces Immediate Availability 71 Patent Issued 71 Nasdaq ENMD 71 Exploit collaboration 71 Cholesterol Drug 71 please visit http:/www.supergen.com 71 Completes Tender Offer 71 RNAi Therapeutics 71 Awarded Patent 71 Advancing Drugs 71 Receives Regulatory 71 THERAPEUTICS 71 Reports Positive 71 MKC# 71 Attracting Bullish Investors 71 Inhalation Aerosol 71 submitted Biologics License 71 Secures Financing 71 Announces Positive 71 Acquires Exclusive 71 Secures Additional 71 Epratuzumab 71 Metastatic Melanoma 71 FDA Approves 71 developing Zerenex TM 71 Patent Covering 71 Announces Issuance 71 Regains Compliance With 71 Regains Compliance 71 Vytorin combines